药剂学专论结课作业概要1.pptVIP

下载本文档

6
0
约1.58万字
约 49页
2018-06-25 发布于浙江
举报
版权申诉

药剂学专论结课作业概要1.ppt

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

药剂学专论结课作业概要1

TRAIL and doxorubicin combination enhances anti-glioblastoma effect based onpassive tumor targeting of liposomes Fig.2.(C) werefluorescence micrographs at 10 × magnification of U87MG cell nuclei and (D) were micrographs at 20× magnification of U87MG cell following 24 h incubation with culture media (1), TRAIL-LP (200 ng/ml) (2), DOX-LP (2μg/ml) (3) or both agents (4). TRAIL and doxorubicin combination enhances anti-glioblastoma effect based onpassive tumor targeting of liposomes Fig.2.(E), Combination treatment of TRAIL-LP and DOX-LP greatly enhanced inhibition of U87MG cells. U87MG cells were seeded in 96-well plates and treated with TRAIL-LP (125 ng/ml), DOX-LP (2μg/ml) or both agents for 24 h, respectively.(F), apoptosis of U87MG cells treated with TRAIL-LP and/or DOX-LP. (G), cell inhibition of BCECs exposed for 24 h to TRAIL-LP (125 ng/ml), DOX-LP (2μg/ml) or both agents,respectively. (H) Apoptosis of BCECs treated with TRAIL-LP and/or DOX-LP TRAIL and doxorubicin combination enhances anti-glioblastoma effect based onpassive tumor targeting of liposomes 4.4 Up-regulation of DR5 is important for DOX-LP to sensitize U87MG cells Fig. 3.(A) Effects of DOX-LP on DR pathway-related proteins. U87MG cells were treated with DOX-LP (2μg/ml) and cell lysates were examined by Western blot. TRAIL and doxorubicin combination enhances anti-glioblastoma effect based onpassive tumor targeting of liposomes Fig.3.(B) Flow cytometry analysis of cell surface expression of DR4 and DR5 in U87MG cells. 1, control cells stained with isotype-matched control IgG. 2, DR4 and DR5 surface expression of untreated U87MG cells. 3, DR4 and DR5 surface expression of U87MG cells treated with DOX-LP. TRAIL and doxorubicin combination enhances anti-glioblastoma effect based onpassive tumor targeting of liposomes Fig.3.(C) DOX-LP sensitize U87MG cells through up-regulation of DR5. U87MG cells were treated with DOXLP (2μg/ml) and/or TRAIL-LP (200 ng/ml) in the presence or absence of DR4/Fc chi